Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

December 5, 2019

Study Completion Date

March 30, 2020

Conditions
HIVContraception
Interventions
DRUG

Levonorgestrel

Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.

DRUG

Efavirenz

Participants will receive efavirenz-based ART as part of standard of care

Trial Locations (1)

Unknown

Infectious Diseases Institute, Kampala

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Infectious Diseases Institute, Uganda

OTHER

collaborator

University of Liverpool

OTHER

collaborator

Northwestern University Feinberg School of Medicine

OTHER

lead

University of Nebraska

OTHER

NCT02722421 - Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women | Biotech Hunter | Biotech Hunter